Neurology News

The federal Physician Self-Referral Law — aka the Stark Law — is a federal statute designed to curb unnecessary utilization of certain health care services.

Idorsia Pharmaceuticals announced that a citizen petition was filed on its behalf, asking the DEA to de-schedule the dual orexin receptor antagonist class of chronic insomnia medications.

Patients with fibromyalgia were at greater risk for pain-related exacerbations of opioid use disorder, according to a study published in Pain.

There is currently a lack of research on obstructive sleep apnea in Latin American women, and one researcher plans to change that with a grant from the CHEST Foundation and the American Academy of Sleep Medicine Foundation.

The FDA has issued a complete response letter to AbbVie regarding its new drug application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

JCR Pharmaceuticals Co. has entered into an agreement with AstraZeneca’s Rare Disease division, Alexion, to develop a novel therapeutic molecule for the treatment of neurodegenerative disease.

Hyperbaric oxygen therapy improved pain symptoms, quality of life and social and emotional function in adults with fibromyalgia after traumatic brain injury compared with pharmacologic intervention, according to research in PLOS One.

CuraSen Therapeutics Inc. announced positive data from its randomized, double-blind crossover phase 2 study of CST-103/CST-107, which demonstrated improvements in cognition and mood in those with Parkinson’s disease.

Being younger at menopause onset and initiating hormone therapy after more than 5 years were both linked to increased tau vulnerability among women, according to a cross-sectional study published in JAMA Neurology.

At the end of 2022, Congress passed a massive 4,155-page spending package that included SECURE Act 2.0, which provided numerous improvements to retirement savings and distribution rules.